Melanocortin Research

PT-141 (Bremelanotide) 10mg

£15.00

PT-141 (Bremelanotide) 10mg · 10mg nominal

Single-material vial listing; lyophilised research product as catalogued. Not a ready-to-use solution, pen or refill. Cyclic melanocortin receptor research and finished-formulation evidence distinctions. For in-vitro laboratory research only; not for human or veterinary use.

Request batch documentation

Description

PT-141 (Bremelanotide) 10mg from Core Research is a research-only catalogue item. Nominal 10mg vial of PT-141/bremelanotide research material. The clinical literature concerns specific studied medicinal preparations; those results are not a validated specification or method of use for this vial. For in-vitro laboratory research only; not for human or veterinary use.

What exactly is supplied?

Nominal 10mg vial of PT-141/bremelanotide research material. The clinical literature concerns specific studied medicinal preparations; those results are not a validated specification or method of use for this vial. The amount on the product name is a catalogue declaration, not a measurement of mass, chemical purity or content for an individual lot. Check the product and the applicable documentation if a specification is essential to your experiment.

Attribute What the product page establishes
Exact catalogue listing PT-141 (Bremelanotide) 10mg
Labelled quantity 10mg nominal per listed item
Presentation Lyophilised vial
Research entity PT-141 (bremelanotide)
Declared use In-vitro laboratory research only; not human or veterinary use
Lot evidence Request the report applicable to the lot and exact format proposed for dispatch

The supplied label and any quality record should identify the lot. If you need the exact chemical form, sequence, terminal groups, counter-ion, mass basis, analytical identity or content, ask for a record tied to this product. Literature references and reference-database formulae are not supplier assay data.

How does this compare with the other formats?

These are separate catalogue products. A name shared across vial, refill and pen listings does not establish identical packaging, fill, solvent, compatibility, concentration or shelf life. A related molecule is not a substitutable chemical merely because it appears in the same research category.

Catalogue item Why the distinction matters
PT-141 (Bremelanotide) 10mg — this listing Single-material vial listing; lyophilised research product as catalogued. Not a ready-to-use solution, pen or refill.
Melanotan II (MT-2) 10mg Related cyclical analogue, not identical to PT-141
MT-2 10mg Pen Different molecule and different supplied format

The comparison with MT-II is scientific, not a recommendation to swap materials. The bremelanotide research vial must be assessed on its own identity and lot documentation; a medicinally studied preparation is not a catalogue variant.

Why is PT-141 (bremelanotide) researched?

PT-141, also called bremelanotide, is a cyclic melanocortin-receptor agonist related structurally to MT-II but distinct in its terminal chemistry. Clinical research on defined bremelanotide preparations is not product evidence for an unrelated lyophilised research vial.

Scope of the studies selected below: Melanocortin receptor signalling, controlled human research on a different finished formulation, and the limits of transferring those findings to a laboratory supply item.

What PT-141 and MT-II share—and where they differ

Melanocortin receptors are G-protein-coupled receptors involved in diverse signalling processes. Their activation can be measured through binding assays, cAMP formation and specific model responses. PT-141 and MT-II occupy this research family, but a shared cyclic scaffold is not a specification of identical sequence, terminal chemistry, receptor response or pharmacokinetics. The exact material named on a supplier report must match the material being purchased.

The site’s MT-II-versus-PT-141 comparison explains why a receptor-targeting shorthand is not an assay result. An analogue can interact with more than one receptor, and a receptor measured in transfected cells does not necessarily predict the magnitude of a response in a living organism. A laboratory comparing these materials therefore needs explicit molecular identity and a defined assay before treating them as interchangeable. 3

Human phase-three research—what was actually tested

Kingsberg and colleagues reported two placebo-controlled, randomised phase-three studies of a specifically formulated bremelanotide investigational medicine in premenopausal women with hypoactive sexual desire disorder. The trials used prespecified desire and distress outcomes; they are not molecular receptor-binding experiments or a study of research-grade lyophilised vials. 1

The trial design matters: a controlled clinical outcome may support conclusions about that studied population and finished intervention, subject to its inclusion criteria and adverse-event findings. It does not validate the supplier’s source, sterility, delivery device, redox chemistry, composition or intended use. No administration method or regimen from the paper belongs on this laboratory catalogue page. 1

Why an extension does not supply a second placebo comparison

Simon and colleagues reported a longer open-label follow-up drawn from participants who had completed the earlier controlled studies and met extension eligibility. Adverse events and questionnaire outcomes were collected, but the extension was not a new blinded randomised comparison. Participation and attrition constrain how broadly its observations may be interpreted. 2

Longer follow-up in one medicinal development programme is important evidence about that programme, not proof that every bremelanotide product has the same safety profile. The Core Research item remains a research material with its own analytical and supplied-format questions. 1, 2

Appropriate scientific boundary

The research literature spans receptor pharmacology and human studies in particular clinical populations. This product page presents that evidence for scientific context, not to propose clinical use. A vial sold as an in-vitro reagent must never be presented as substitutable for a regulated medicine, even if a similar molecule appears in its published studies.

What analytical evidence matters for this exact item?

A relevant certificate or analytical report should identify the tested material, reported lot, form and method. Separate identity (what was tested), purity (how the major signal relates to impurities under one method), content (how much material was measured) and the packaging/fill specification. A cited paper investigates the research entity; it does not certify the vial or cartridge supplied here.

Use Batch Documentation to enquire before purchase, specifying “PT-141 (Bremelanotide) 10mg” and your required tests. No existing order or container lot is needed to make a pre-purchase enquiry under Core Research’s published documentation route. After delivery, match the returned report to the supplied lot rather than assuming a certificate for another item applies.

The guide to reading a peptide CoA explains how to identify the tested sample; the HPLC guide distinguishes chromatographic peak area from measured content, and the mass-spectrometry guide explains how observed ions and expected identity differ. An absent lot-specific result is treated as unknown, never as a default purity or sterility claim.

Check PT-141 rather than an MT-II analogue

The identity report needs to tie the exact cyclic peptide and terminal form to the measured material. Receptor studies and clinical formulation records are contextual scientific evidence; neither can substitute for product-specific chemistry, content or release results.

Vial format and nominal amount

This product is the standalone vial listing. A nominal dry-material amount is not an aqueous concentration, a number of samples or a verified peptide-content assay. Any solution properties depend on the actual compound form, solvent, container, method and controls, which this page does not specify.

Storage, dispatch and laboratory receiving

Follow the conditions documented on the supplied label or applicable product/lot specification. Fixed refrigerated/frozen shelf lives, dry-product expiry, prepared-solution lifetime and transport-temperature promises are not inserted without appropriate evidence. An unopened material and a prepared solution have different possible stability concerns.

Exact cyclic-peptide identity, counter-ion and formulated state may affect how results from solution and solid-state studies are compared. Product-specific validated storage conditions take precedence over generic peptide advice.

At receipt, record the name, quantity, batch/lot identifier, packaging condition and closure. Compare them against the purchase record and any available certificate. The research-product receiving checklist provides the workflow; for delayed or unexpectedly warm deliveries use the arrival-condition guide and retain photographs/tracking where relevant.

Core Research publishes UK dispatch from Birmingham and plain, unmarked outer packaging. Tracking is supplied where provided by the chosen service. The actual delivery charge and expected timing depend on destination, order and checkout options; no universal next-day or temperature-controlled service is promised by this product draft.

Ordering and support

Select the desired quantity using the native WooCommerce purchase panel; current price, availability and the available checkout methods are determined by the live site, not by this static description. For supplier, material or lot questions, contact Core Research before placing an order.

Request batch documentation · Ask about this product · Institutional procurement · Shipping & Delivery

The supplied research material is not intended for clinical treatment, disease prevention, human or veterinary administration, food, cosmetic self-use or any unsupervised personal procedure.

Frequently asked ordering and laboratory questions

What is included in this product?

Single-material vial listing; lyophilised research product as catalogued. Not a ready-to-use solution, pen or refill. The catalogue amount is 10mg nominal. Confirm any accessory, packaging or filled-state requirement before buying.

Can I request batch documentation before ordering?

Yes. The published documentation route accepts pre-purchase enquiries naming the product and presentation. Ask for the actual tests and lot applicability needed by your laboratory; a reply or historical certificate should not be mistaken for a guaranteed current-lot assay.

Does the labelled amount determine the concentration or experimental sample count?

No. A labelled mass is not a liquid volume or measured solution concentration. Experimental consumption depends on method, assay design and validated material-content basis. This page does not provide a preparation or use protocol.

Is this a medicinal or ready-to-administer product?

No. This listing is restricted to in-vitro laboratory research and does not provide a therapeutic, cosmetic, veterinary or personal-use indication.

What research finding is most important to interpret carefully?

Controlled human bremelanotide trials tested a particular finished medicinal intervention in a defined population, not Core Research’s research vial.

How do delivery and institutional quotations work?

Use the live checkout for the available price, stock, shipping methods and final charge. Institutions can request quotations or purchase-order references through Core Research’s procurement route; raise any specific lot or documentation condition before ordering.

What should we do if the item is damaged or labelled incorrectly?

Preserve the packaging and lot information, take clear photographs and contact Core Research with your order details before using the material in an experiment.

Research references

[1] Kingsberg SA et al. (2019). Two randomised, placebo-controlled phase-three bremelanotide trials. PMID 31599840. View research record

[2] Simon JA et al. (2019). Open-label long-term extension of the RECONNECT programme. PMID 31599847. View research record

[3] Bednarek MA et al. (2008). MT-II-related cyclic melanocortin analogue receptor assays (comparison context only). PMID 18378043. View research record

Additional information

Format

Vial

Strength

10mg